Sam Brusco, Associate Editor02.23.22
Verterbral implant firm Implanet completed the first U.S. surgeries using its ORIGIN cervical plate, acquired from Orthopaedic & Spine Development (OSD) last March.
Implanet began promoting the ORIGIN range of anterior cervical plates in the U.S. in late 2021. The plates received EU approval in 2009, and U.S. Food and Drug Administration (FDA) 510(k) clearance in 2020.
“I regularly use cervical plates in my surgical practice,” Phillip Esce MD of Carolina Orthopaedic & Neurosurgical Associates told the press. “This new implant was easy and fast to use during the first cases, and the post-operative clinical outcome is highly satisfactory. We will now monitor these patients to confirm the results over the longer term.”
“These first implantations are the consequence of the synergies resulting from our merger with OSD, reflecting the advantages of expanding our range of implants for spine surgery,” added Implanet CEO Ludovic Lastennet. “We intend to build on this initial success and intensify our commercial approach, notably in the United States. Our network of agents will now be able to present surgeons with an enhanced range that includes the ORIGIN cervical plate, which has CE marking and FDA clearance. This first step should rapidly lead us to establish our offer on the American market in the field of cervical spine surgery, estimated at $1.35 billion with over 368,000 surgeries1."
The plates are not at the heart of Implanet’s portfolio and have enabled many commercial agreements, for example the partnership began with ulrich medical last year.
Reference
1 Source Global Market Model 2018
Implanet began promoting the ORIGIN range of anterior cervical plates in the U.S. in late 2021. The plates received EU approval in 2009, and U.S. Food and Drug Administration (FDA) 510(k) clearance in 2020.
“I regularly use cervical plates in my surgical practice,” Phillip Esce MD of Carolina Orthopaedic & Neurosurgical Associates told the press. “This new implant was easy and fast to use during the first cases, and the post-operative clinical outcome is highly satisfactory. We will now monitor these patients to confirm the results over the longer term.”
“These first implantations are the consequence of the synergies resulting from our merger with OSD, reflecting the advantages of expanding our range of implants for spine surgery,” added Implanet CEO Ludovic Lastennet. “We intend to build on this initial success and intensify our commercial approach, notably in the United States. Our network of agents will now be able to present surgeons with an enhanced range that includes the ORIGIN cervical plate, which has CE marking and FDA clearance. This first step should rapidly lead us to establish our offer on the American market in the field of cervical spine surgery, estimated at $1.35 billion with over 368,000 surgeries1."
The plates are not at the heart of Implanet’s portfolio and have enabled many commercial agreements, for example the partnership began with ulrich medical last year.
Reference
1 Source Global Market Model 2018